Analyst Price Targets — GPCR
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| June 11, 2026 10:42 am | Ananda Ghosh | H.C. Wainwright | $70.00 | $41.53 | StreetInsider | Structure Therapeutics (GPCR) PT Lowered to $70 at H.C. Wainwright |
| April 27, 2026 9:55 am | — | Canaccord Genuity | $101.00 | $45.49 | TheFly | Structure Therapeutics initiated with a Buy at Canaccord |
| March 17, 2026 12:29 pm | Evan Seigerman | BMO Capital | $145.00 | $56.88 | StreetInsider | Structure Therapeutics (GPCR) PT Raised to $145 at BMO Capital |
| January 20, 2026 12:20 pm | — | Guggenheim | $140.00 | $88.64 | TheFly | Structure Therapeutics price target raised to $140 from $90 at Guggenheim |
| January 19, 2026 10:26 pm | — | Goldman Sachs | $102.00 | $88.64 | TheFly | Structure Therapeutics moved to Buy rating at Goldman Sachs |
| December 19, 2025 1:43 pm | Ananda Ghosh | H.C. Wainwright | $90.00 | $66.45 | TheFly | Structure Therapeutics price target raised to $90 from $60 at H.C. Wainwright |
| December 12, 2025 1:10 pm | Terence Flynn | Morgan Stanley | $125.00 | $66.24 | TheFly | Structure Therapeutics price target raised to $125 from $120 at Morgan Stanley |
| December 11, 2025 2:12 pm | — | Jefferies | $125.00 | $69.64 | TheFly | Structure Therapeutics price target raised to $125 from $79 at Jefferies |
| December 8, 2025 9:03 pm | — | Stifel Nicolaus | $90.00 | $69.98 | TheFly | Structure Therapeutics price target raised to $90 from $50 at Stifel |
| December 2, 2025 2:21 pm | Annabel Samimy | Stifel Nicolaus | $50.00 | $33.89 | StreetInsider | Stifel Reiterates Buy Rating on Structure Therapeutics (GPCR) |
Latest News for GPCR
Five years after Wegovy's FDA approval, the obesity drug market has evolved rapidly. Novo Nordisk and Eli Lilly introduced GLP-1 pills this year and others like Structure Therapeutics and Zealand Pharma are trying to fight for market share.
Structure Therapeutics advances aleniglipron, a potential best-in-class oral GLP-1, into Phase 3 for obesity, supported by strong Phase 2b data. GPCR's $1.5B cash position and a projected cash runway through 2028 underpin its ability to execute pivotal trials and commercial plans. My SOTP analysis yields a fair value of $42.49/share, with aleniglipron's risk-adjusted NPV at $1.34B and pipeline assets included at no…
Structure Therapeutics Inc. (GPCR) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Structure Therapeutics said on Friday its experimental GLP-1 obesity pill did not show any signs of drug-induced liver injury, and patients continued to lose weight even on the lower doses of the drug.
Publication presented concurrently with oral presentation at American Diabetes Association's 86th Scientific Sessions from ACCESS development program with aleniglipron, a once-daily oral small molecule GLP-1 receptor agonist
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
No House trades found for GPCR.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.